Why XPOVIO® (selinexor)?

    XPOVIO is the f‌irst and only FDA-approved oral medicine of its kind that may treat relapsed or refractory dif‌fuse large B-cell lymphoma (RR DLBCL), even if other treatments no longer work for you.

    XPOVIO is a pill you take by mouth at home
    Human body icon Human body icon

    You DO NOT have to go to
    the hospital to take XPOVIO

    You DO NOT have to take
    XPOVIO with any other anti-cancer
    RR DLBCL medication

    XPOVIO is targeted therapy, NOT chemotherapy

    Kills at the cell core
    XPOVIO works at the core of the cell (the nucleus) to kill some cancer cells
    Responses were meaningful
    29% of patients showed improvement with XPOVIO

    The National Comprehensive Cancer Network® (NCCN) recommends selinexor (XPOVIO) for patients with RR DLBCL who have had at least 2 prior lines of systemic therapy and whose disease no longer responds to certain treatment options*

    *Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas. V.4.2020. © 2020 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed August 14, 2020. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

    What is XPO1, and why does it matter?

    XPO1 is a protein that maintains balance in healthy cells so they can function properly

    • Cells have important anti-cancer materials that can only work in the cell’s core (the nucleus)
    • XPO1 is a protein that carries these materials from the nucleus to another part of the cell (the cytoplasm)
    • To keep the cell in balance, XPO1 only carries the right amount of anti-cancer materials out of the nucleus
    Labeled image of XPO1 in a healthy cell

    How does XPOVIO work to block XPO1?

    Annotated diagram showing how XPOVIO® (selinexor) works Annotated diagram showing how XPOVIO® (selinexor) works

    What is dif‌fuse large B-cell lymphoma (DLBCL)?

    DLBCL is a cancer that starts in B cells, a type of white blood cell. White blood cells are part of the immune system, which helps the body fight infection and disease. DLBCL can spread to other cells, organs, and tissues in the body.

    What is relapsed or refractory DLBCL (RR DLBCL)?

    RR DLBCL is cancer that has come back after treatment (relapse) or has stopped responding to certain treatments (refractory).

    RR DLBCL is treatable but may no longer be curable.

    When DLBCL relapses, your doctor may start you on another
    type of treatment to help you get your disease under control

    How will my healthcare provider treat RR DLBCL?

    There are different options for treating RR DLBCL, including:

    Chemotherapy

    Usually taken by mouth, injection, or infusion with or without other treatments to kill cancer cells

    Stem Cell
    Transplants

    Gives patients healthy stem cells (the blood-forming cells in the body) to replace their damaged cells

    Cell Therapies

    Certain cells are taken from a patient’s blood and altered in a laboratory so they will fight cancer. The cells are then put back into the patient by infusion

    New Therapies

    New types of medicines that fight RR DLBCL in different ways

    How will my healthcare provider and I choose a treatment?

    You and your healthcare provider will decide together which treatments are right for you.

    Some factors your may consider are:

    Time icon

    How long the treatment has been shown to work in patients with RR DLBCL

    Other health issues icon

    Other health issues you may have

    Warning icon

    Possible side effects of treatment

    Other treatments icon

    Treatments you have taken before

    Hospital icon

    If you are able to get to a clinic for
    your treatment

    What is XPOVIO?

    XPOVIO® (selinexor) is a prescription medicine used:

    • in combination with dexamethasone to treat adults with multiple myeloma (MM) that has come back (relapsed) or that did not respond to previous treatment (refractory), and
      • who have received at least 4 prior therapies, and
      • whose disease did not respond (refractory) to at least 2 proteasome inhibitor medicines, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody medicine

    What is the most important information I should know about XPOVIO?

    Your healthcare provider will do blood tests before you start taking XPOVIO, and often during the first 3 months of treatment, and then as needed during treatment to monitor you for side effects. Your healthcare provider may change your dose of XPOVIO, stop your treatment for a period of time, or completely stop your treatment if you have certain side effects during treatment with XPOVIO.